Ramandeep Rattan

This study identifies treatment-specific miRNA response signatures in RRMS patients following cladribine or ocrelizumab, revealing distinct molecular programs associated with each therapy.

This study identifies succinate accumulation in aged ovarian tumor microenvironments as a driver of Treg dysfunction, suggesting metabolic targeting as a strategy to restore antitumor immunity.

This study identifies Irg1 as a protective gene that negatively regulates pathogenic Th17 cells in CNS autoimmunity using knockout mice and single-cell RNA sequencing.

This study shows CPI-613 reduces tumor growth in chemoresistant ovarian tumors by inhibiting mitochondrial function and enhancing chemotherapy response.

This study uses untargeted metabolomics to identify altered serum metabolites distinguishing relapsing-remitting MS, progressive MS, and healthy subjects.

The paper identifies altered omega fatty acid-derived lipid mediators in RRMS patients using metabolipidomics, suggesting their potential as biomarkers for diagnosis and prognosis.

This study shows that MaR1 treatment reduces inflammation, protects neurons, and improves metabolism in a mouse model of multiple sclerosis.

This study shows that pyruvate dehydrogenase (Pdh) activity is critical for oligodendrocyte maturation and remyelination by regulating mitochondrial respiration and Olig1 acetylation.

The paper identifies altered metabolic pathways in RRMS patients using metabolomics and shows that targeting glycolysis can reduce disease progression in a mouse model.